Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Protagonist Therapeutics, Inc (PTGX)
Price$145.72Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $46.0M | $434.4M | $60.0M | $26.6M | $27.4M | $28.6M | $231,000 | $30.9M | $20.1M | — | — | — |
| Research & development | $159.3M | $138.1M | $120.2M | $126.2M | $126.0M | $74.5M | $65.0M | $59.5M | $46.2M | $25.7M | $11.8M | $7.5M |
| Operating expenses | $204.1M | $181.6M | $153.7M | $158.0M | $153.2M | $93.1M | $80.8M | $73.2M | $58.0M | $32.7M | $14.8M | $9.3M |
| Operating income | −$158.1M | $252.8M | −$93.7M | −$131.4M | −$125.8M | −$64.5M | −$80.5M | −$42.3M | −$37.9M | −$32.7M | −$14.8M | −$9.3M |
| Operating margin | −343.63% | 58.20% | −156.09% | −494.24% | −460.01% | −225.36% | −34,857.58% | −136.68% | −188.89% | — | — | — |
| EBITDA | −$156.8M | $253.7M | −$92.7M | −$130.3M | −$125.0M | −$63.6M | −$79.8M | −$41.7M | −$37.5M | −$32.3M | −$14.5M | −$9.1M |
| EBITDA margin | −340.85% | 58.39% | −154.46% | −490.35% | −457.04% | −222.05% | −34,540.69% | −134.98% | −186.87% | — | — | — |
| Net income | −$130.1M | $275.2M | −$79.0M | −$127.4M | −$125.6M | −$66.2M | −$77.2M | −$38.9M | −$37.0M | −$37.2M | −$14.9M | −$11.1M |
| Net profit margin | −282.83% | 63.34% | −131.59% | −479.26% | −458.94% | −231.07% | −33,414.29% | −125.87% | −184.20% | — | — | — |
| Basic EPSper basic share | -$2.05 | $4.47 | -$1.39 | -$2.60 | -$2.71 | -$1.92 | -$2.98 | -$1.74 | -$2.09 | -$5.80 | -$59.32 | -$49.38 |
| Diluted EPSper diluted share | -$2.05 | $4.23 | -$1.39 | -$2.60 | -$2.71 | -$1.92 | -$2.98 | -$1.74 | -$2.09 | -$5.80 | -$59.32 | -$49.38 |
Owners
Reported shareholders
15.94%of listed shares
BlackRock, Inc.10.31M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 15.94%10.31M shares |
FARALLON CAPITAL MANAGEMENT, L.L.C. | 9.82%6.35M shares |
RTW INVESTMENTS, LP | 7.83%5.06M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.61%3.63M shares |
WELLINGTON MANAGEMENT GROUP LLP | 5.28%3.42M shares |
UBS Group AG | 5.26%3.4M shares |
STATE STREET CORP | 5.14%3.32M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.41%2.85M shares |
JOHNSON & JOHNSON | 3.79%2.45M shares |
Invesco Ltd. | 3.62%2.34M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 3.32%2.15M shares |
Jupiter Topco LLC | 3.29%2.13M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.69%1.74M shares |
Woodline Partners LP | 2.19%1.41M shares |
BANK OF AMERICA CORP /DE/ | 2.05%1.32M shares |
JENNISON ASSOCIATES LLC | 1.78%1.15M shares |
PERCEPTIVE ADVISORS LLC | 1.52%981.88K shares |
ADAR1 Capital Management, LLC | 1.49%960.86K shares |
MORGAN STANLEY | 1.40%905.99K shares |
Alyeska Investment Group, L.P. | 1.38%889.3K shares |
Percentages use 64.67M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 · 10b5-1 | Waddill William D.Director | SellCommon Stock | 9.0K | $117.94 | $1.06M | 7.8K |
| Jun 10, 2026Form 4 · 10b5-1 | Waddill William D.Director | SellCommon Stock | 9.0K | $107.68 | $969.1K | 7.8K |
| May 29, 2026Form 4 · 10b5-1 | Waddill William D.Director | SellCommon Stock | 9.0K | $99.64 | $896.8K | 7.8K |
| May 12, 2026Form 4/A · 10b5-1 | PATEL DINESH V PH DPresident and CEO | SellCommon Stock | 75.0K | $100.12 | $7.51M | 523.5K |
| May 12, 2026Form 4 | PATEL DINESH V PH DPresident and CEO | SellCommon Stock | 75.0K | $100.12 | $7.51M | 523.5K |